These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12205059)

  • 1. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
    J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Rubinstein E
    J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
    García-Olmos M; Parra A; García-Calvo G; Ponte C; Giménez MJ; Aguilar L; Soriano F
    Int J Antimicrob Agents; 2003 Jun; 21(6):568-73. PubMed ID: 12791471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
    Croisier D; Etienne M; Bergoin E; Charles PE; Lequeu C; Piroth L; Portier H; Chavanet P
    Antimicrob Agents Chemother; 2004 May; 48(5):1699-707. PubMed ID: 15105123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
    Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
    Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
    Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
    Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
    Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
    Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
    Cottagnoud P; Cottagnoud M; Acosta F; Flatz L; Kühn F; Stucki A; Entenza J
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):656-62. PubMed ID: 14557920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro.
    Kühn F; Cottagnoud M; Acosta F; Flatz L; Entenza J; Cottagnoud P
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2487-91. PubMed ID: 12878509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
    Reinert RR; Lütticken R; Lemperle M; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
    Flatz L; Cottagnoud M; Kühn F; Entenza J; Stucki A; Cottagnoud P
    J Antimicrob Chemother; 2004 Feb; 53(2):305-10. PubMed ID: 14729741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.